CSPC Pharma wins China’s mRNA vaccine race, but just not fast enough
Drugmaker CSPC Pharma gets the green light to produce China’s first homegrown mRNA vaccine, but the breakthrough comes too late in the pandemic to impress investors Key Takeaways: News of…
1093.HK
VNET mired in mess of red ink, chairman’s dubious stock maneuvers
The data center operator’s net loss widened in last year’s final quarter, while a maneuver by its chairman to retain control of the company may leave many investors uneasy Key…
VNET.US
NetDragon still learning how to profit from education, as investors grow impatient
The company’s education unit overtook its older gaming division in terms of revenue last year, even as the former lost money Key Takeaways: NetDragon’s revenue fell 1.5% in the second…
0777.HK
Zhihu seeks answer to profit challenge as its businesses grow apart
The online Q&A platform often called the ‘Quora of China’ saw its losses widen in 2022, as it posted a 12th consecutive quarter in the red at the end of…
2390.HK
ZH.US
XPeng revs up for comeback after ending 2022 in the slow lane
The electric vehicle maker forecast its deliveries would drop about 46% in the first quarter, but expects to rebound in the second half with a steady stream of new product…
9868.HK
XPEV.US
Wuxi AppTec finds bitter aftertaste in waning demand for Covid drug services
The leading Chinese CXO posted record revenue and strong profits last year, but its growth started to slow in the fourth quarter Key Takeaways: Wuxi AppTec’s chemical business doubled last…
2359.HK
603259.SHG
Kanzhun cranks up spending, even as others tighten belts
China’s leading online recruitment platform’s operating costs soared 70% in last year’s fourth quarter, pushing the company into the red Key Takeaways: Kanzhun’s revenue was flat in the fourth quarter,…
BZ.US
2076.HK
